Phathom Pharmaceuticals, Inc. Enterprise Value

Enterprise Value of PHAT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Enterprise Value growth rates and interactive chart. Calculated as market cap + net debt. A company with a market cap of $1 billion and net cash of $500 million will have an enterprise value of $500 million. Not applicable to financial companies, due to the structure of cash on their balance sheet.


Highlights and Quick Summary

Visit stockrow.com/PHAT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Enterprise Value of Phathom Pharmaceuticals, Inc.

Most recent Enterprise Valueof PHAT including historical data for past 10 years.

Interactive Chart of Enterprise Value of Phathom Pharmaceuticals, Inc.


Business Profile of Phathom Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.